INTRODUCTION
Systemic lupus erythematosis (SLE) is an inflammatory disorder that affects virtually all organs of the body. It is associated with significant morbidity and mortality. Mainstay of treatment of SLE is based upon preventive measures as early detection can significantly change the outcome of
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Renal Biopsy: A much needed tool in patients with Systemic Lupus Erythematosis (SLE) the disease. Kidneys are frequently affected in SLE. The earliest manifestation of renal involvement being an abnormal urine sediment, with proteinuria being the most frequent abnormality. 1 The renal function may be normal even with significant involvement histologically.
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The incidence of lupus nephritis is high in Asians ranging between 33%-55%. 5, 6 Most renal abnormalities emerge soon after diagnosis(usually within first 6-36 months). 1, 5, 7 Renal involvement in SLE is diagnosed either with routine urinalysis, looking for protein and hematuria, an estimation of urine protein excretion and elevated serum creatinine. Confirmation is usually done by renal biopsy, as staging of the disease is important, since the treatment varies with the staging and clinical presentation may not accurately reflect the severity of histologic findings.
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We conducted this study to see if clinical renal parameters could predict the histologic staging and if renal biopsy could be avoided and treatment decision could be taken based on clinical grounds.
METHODS
After informed consent and ethical committee approval of the hospital conducting the study, retrospective analysis of all patients with SLE that underwent renal biopsy between January 2012 and December 2014 was done. The study was conducted in department of Nephrology, Liaquat National Hospital Karachi. We studied 51 patients of lupus nephritis. SLE was diagnosed with a positive ANA and anti dsDNA. Patient's demographic characteristics, urine analysis at the time of renal biopsy, serum creatinine and 24 hours urine collection for protein was noted. Patients clinical staging based on these parameters is shown in Table-I. Urinalysis was done for the presence or absence of proteinuria, hematuria or both. Proteinuria was positive if urine dipstick was positive for protein, Hematuria was defined as RBC > 5 RBC/HPF. Serum creatinine of >1.2mg/dl was considered abnormal for females and creatinine of >l.4mg/dl was considered abnormal for males. 24 hours urine collection for protein was considered nonnephrotic if protein was 300-2999 mg/24 hours in urine and > 3 gm /24hrs protein was considered nephrotic. Staging based on Histology is shown in Table- II. Inclusion Criteria: All patients with SLE of both gender who underwent renal biopsy, and had serum creatinine, urinalysis and 24 hours urine protein measurements were included. Exclusion Criteria: Patients were excluded if SLE patients renal biopsy had inadequate specimen and diagnosis was inconclusive. In addition if any of the laboratory parameter was missing that patient was excluded from the study. Patients already on immunosuppressant or anti-proteinuric medication and patients who had other concomitant disease other than lupus nephritis on renal biopsy were also excluded. Statistical Method: Data were collected on pre designed Performa, and analyzed using SPSS version 17. Chi-square test was used to analyze categorical data and p<0.05 was considered significant. Cohen's kappa (κ) analysis was used to examine the agreement between two diagnostic methods i.e. clinical parameter and histologic finding on renal biopsy with values ≤ 0 as indicating no agreement, 0.01-0.20 as none to slight, 0.21-0.40 as fair, 0.41-0.60 as moderate, 0.61-0.80 as substantial, and 0.81-1.00 as almost perfect agreement. P value <0.05 indicates that agreement was unlikely due to chance alone.
RESULTS
Total 51 patients were enrolled based on inclusion and exclusion criteria. Among 51 patients analyzed, 37 patients were females (72.5%) and 14 patients were males (27.5%) with mean age of 32.51± 16 with 2 patients(25%) while 3 patients (37.5%) were in stage V, 2 (25%) were in stage III and 1 patient(12.5%) was in stage IV on biopsy report. Similarly, for stage III lupus nephritis, 05 (35.7%) out of 14 patients, laboratory and histopathology results were matched. One patient (7.14%) was found to have stage II, 7 patients (50%) were in stage IV and 1 patient (7.1) was in stage V lupus nephritis on histopathology results.
There were 20 patients labeled stage IV lupus nephritis on laboratory parameters. Among them 12 (60%) patients histopathology report found the same stage while 3 patients (15%) were in stage III, 4 patients (20%) were in stage V and 1 patient (5%) labeled stage VI on biopsy report.
Nine patients labeled stage V on laboratory parameters were compared with their histopathology findings, only 2 (22.2%) patients results were matched while 6(66.6%) were in stage IV and 1 (11.1%) was in stage III.
This indicates the fact that it is inadequate to rely on laboratory impression solely for starting treatment and renal biopsy should be performed in all cases of SLE having any urinary abnormality.
DISCUSSION
Lupus nephritis has varied clinical presentation. Urinary abnormalities especially proteinuria is the cardinal feature of the disease. 25% of patients may have abnormal urine sediment at the time of diagnosis and 60% will develop some abnormality during their illness. 12 The decision of when to perform renal biopsy in lupus nephritis is variable. Some studies recommend biopsy when patients have > 500 mg protein/24hours 13 in the absence of renal failure, while others recommend biopsy only when proteinuria is >1000 mg/24 hours and abnormal urine sediment.
14 Several case series have demonstrated that significant renal damage may be present without clinical signs of renal involvement in advanced staging of lupus nephritis(stage III,IV). 2, 3, 15 Since early diagnosis can change the renal outcome, 16, 17 it is imperative that correct diagnosis be made. Our study reinforces this concept as 17/51 (33.3%) of patients, thought to have stages that did not require aggressive immunosuppressant therapy actually had advanced stages proven on renal biopsy that warranted institution of early immunosuppressant therapy. Our results are similar to results reported by Lisa Christopher et al. in which 55% of patients with low grade proteinuria had advanced Stage 3 or 4.
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Our study is an eye opener, as patients with SLE are usually treated by Rheumatologists and they follow clinical renal parameters to diagnose staging of lupus nephritis. In a survey done at JHUSOM, involving rheumatologists 37% would not refer the patient to a nephrologist with proteinuria <1000mg/24 hours and 17% would not refer even in the presence of hematuria.
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Limitations of the study: We did not considered C3 levels and anti-ds DNA titers as they may influence the clinical staging, since studies have suggested that these parameters are indicative of proliferative stages. In addition, it is limited by a small sample size, but still the results are significant and need further studies as it may have a very important role in preventing long term renal outcome.
CONCLUSION
Staging of lupus nephritis done on basis of laboratory findings did not correlate well with the underlying histopathological staging, and therefore, renal biopsy is an essential tool to approach lupus nephritis in order to provide timely and appropriate treatment to patients. We advocate early renal biopsy in all patients with LN, regardless of degree of proteinuria or renal function.
